Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Case report of a patient with stage IV lung adenocarcinoma and uncommon/compound EGFR mutations who responded to afatinib

Published:2024 Issue: Volume:51 Page:102094
ISSN:2213-0071
Container-title:Respiratory Medicine Case Reports
language:en
Short-container-title:Respiratory Medicine Case Reports

Author:

Hirokawa Hisanori,Hirata Hirokuni^ORCID,Azuma Hayase,Sugitate Kei,Soda Sayo,Matsushima Jun,Fukushima Yasutsugu

Publisher

Elsevier BV

Reference12 articles.

1. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial;Oizumi;Oncol.,2012

2. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals;Zhu;Cancer Lett.,2008

3. Overall survival with osimertinib in untreated, EGFR mutated advanced NSCLC;Ramalingam;N. Engl. J. Med.,2020

4. Guidelines for EGFR gene mutation testing in lung cancer patients ver. 5.0, The Japan Lung Cancer Society.

5. Afatinib for the treatment of nsclc harboring uncommon EGFR mutations: a database of 693 cases;Yang;J. Thorac. Oncol.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP